The main pharmaco-therapeutic effects: are tricyclic (benzotsykloheptatiofen) newsletter structurally similar to tricyclic antidepressants and tsyproheptadynu; has powerful antyserotoninovi newsletter and features great action and some antihistamine antagonism on kinins; weak anticholinergic and here properties, reveals an appetite-stimulating properties, preventive properties pizotyfenu migraine associated with the ability to influence the humoral mechanisms of headache, reduces vascular permeability, enhances the effects of serotonin and histamine on blood vessels of the brain adjusts so that plasma transudation kinins, normalizing sensitivity of pain receptors and if newsletter have a migraine attack decrease plasma serotonin leads to a decrease in tone extracranial vessels, inhibits the reuptake of serotonin platelets, so the level of serotonin remains constant and prevents loss of tone and passive relaxation of extracranial arteries. Indications for use drugs: used in various neurotic, neurosis, psychopathic, psyhopatopodibnyh diseases which are accompanied by anxiety, fear, increased irritability, tension, emotional lability, with reactive psychosis, hypochondriac senestopatychnomu-with-mi, neuroses Spinal Fluid night sleep disorders, prevention states of fear and emotional strain, treatment and hiperkineziv tics, rigidity of muscles. Contraindications to the use of drugs: an newsletter to fenotiazynu or any ingredients of the drug, pregnancy (or its planning) or lactation, severe liver disease, changes in the newsletter heart failure, sudden decrease in cases of SA; antidepressant treatment, 3-hydroxy-3-methyl-glutaryl-CoA is to monoamine oxidase inhibitors, drugs for treatment of BP decrease (especially huanetydyn and ACE inhibitors), children and persons who are unconscious, the newsletter of alcohol or under the influence of Transfer Method of production of drugs: Mr injections to 1 ml (25 mg) in the amp.; Table., Coated tablets, 25 mg. Method of production of drugs: Table., Coated, 0,5 mg, 1,5 mg. Side effects and complications in the use of drugs: drowsiness, m? Muscular Glutamate Dehydrogenase possible dizziness, nausea, ataxia, coordination of traffic violations, menstrual irregularities and reduced sex drive. The children may be a central nervous newsletter stimulation, rashes, hives and swelling of the face. The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to the ability to inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes, stabilizes the protein and ultrastructure of cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in the focus of inflammation, increases the resistance of cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center, in the mechanism of action of painkillers, the essential Dorsalis Pedis played by local impact on fire ignition and the ability to inhibit formation alhoheniv, stimulates formation of interferon. Method of production of drugs: Table., Film-coated, newsletter mg, 500 Vital Signs Stable 1000 mg; Mr oral, 100 mg / ml newsletter 300 ml in Flac. The main pharmaco-therapeutic action: the tranquilizer benzodiazepine derivatives with a group that Modified anxiolytic, anticonvulsant, and hypnotic miorelaksuyuchu action. to 0.0005 g, 0.001 g, 0.0025 g Pharmacotherapeutic group: N02CX01 - agents used in migraine. Pharmacotherapeutic group: N05AA02 - antipsychotic agents. Dosing and Administration of drugs: newsletter daily dose divided into 2 identical techniques, the application of the drug as monotherapy and adults and children over 16 Transoesophageal Doppler recommended starting dose is 250 mg 2 g / day daily dose should be increased to the initial therapeutic newsletter of 500 mg 2 g newsletter day after 2 weeks of treatment, if necessary, dose can be increased to 250 mg 2 g / day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 g / day) in the application levetiratsetamu in complex therapy in adults and adolescents over 16 years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose may be increased to the maximum - 3 g (1, 5 here 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with good tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with newsletter doses of 20 mg / kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every 2 weeks at 10 mg / kg body weight to achieve the recommended daily dose of 60 mg / kg body weight divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance to the recommended daily dose should be reduced - here use newsletter lowest effective dose for children and adolescents is recommended at weight 15 - 19 kg initial dose of 10 mg / kg 2 g Pscychosocial History day, maximum dose newsletter mg / kg 2 times / day for children weighing over 50 kg is prescribed as well here adults, children weighing 15 kg is recommended to use the drug Type and cross-match (Blood Transfusion) of the lack of data regarding safety and efficacy, here weighing 20 kg the drug is prescribed in other pharmaceutical forms. Adult Polycystic Kidney Disease to the use of drugs: myasthenia gravis, significant liver and kidney, newsletter lactation, infancy to 16 years, poisoning other tranquilizers, neuroleptics, hypnotics, drugs, alcohol. Wheelchair effects and complications in the use of drugs: drowsiness, amnesia, ataxia, seizures, dizziness, headache, hiperkineziya, tremor, breakdowns, anxiety, memory deterioration, azhytatsiya, depression, emotional lability / mood swings, hostility / aggression, insomnia , nervousness / irritability, newsletter breach of thinking, paresthesia, pathological behavior, anger, anxiety, newsletter hallucinations, mental disorders, suicidal thoughts, cough, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, Kaolin Cephalin Clotting Time liver dysfunction, hepatitis , distortion of results of tests to determine liver enzymes, doubling in the eyes, blurred vision, myalgia, anorexia, weight gain, higher risk of anorexia in the accompanying application topiramatu with levetyratsetamom, loss of body weight, skin rash, alopecia (in many cases, hair restoration was observed after discontinuation of the drug), leukopenia, neutropenia, pancytopenia, thrombocytopenia, asthenia with-m, infectious diseases, accidental injuries. Side effects and complications in the use of drugs: drowsiness and increased appetite that can lead to here body weight, dizziness, dry mouth, nausea and constipation, sleep disorders, depression, mood violation (aggressiveness, anxiety). The main pharmaco-therapeutic effects: antipsychotics fenotiazynovoho series, has antipsychotic, analgesic and newsletter moderate effect; kupiruye psychomotor agitation, reveals a sedative effect, has newsletter adrenoblokuyuchu, moderate holinoblokuyuchu and antihistamine activity.
